Education
About Us
Working with TipRanks
Follow Us
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
IOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.64 - $12.51
Previous CloseN/A
Volume2.95M
Average Volume (3M)15.67M
Market Cap
$554.33M
Enterprise ValueN/A
Total Cash (Recent Filing)$323.78M
Total Debt (Recent Filing)$58.26M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Aug 07, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding333,934,400
10 Day Avg. Volume27,168,469
30 Day Avg. Volume15,669,607
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)1.45
Price to Sales (P/S)0.00
P/FCF Ratio-3.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.54Price Target Upside595.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Cash ReservesThe company ended the quarter with $323.7 million of cash, which, along with future revenue, should fund all ongoing operations into the second half of 2026.
Efficacy RecognitionTIL therapy has set a new standard for efficacy in melanoma, and Iovance is recognized for being the first to commercialize this complex product.
Market ExpansionIovance Biotherapeutics plans to accelerate growth by focusing on entering ex-U.S. markets such as the U.K., E.U., and Canada.
Bears Say
Market CompetitionThe melanoma space is becoming increasingly crowded.
Revenue Guidance DowngradeThe company decreased revenue guidance to $250-300MM (previously $450-475MM) and attributed this to a slower ramp in ATCs.
Revenue ShortfallIovance reported total Q1 revenue of $49.3MM (-33% Q/Q), which missed consensus of $82MM by 40%.
---
Ownership Overview
0.30% Insiders
17.95% Mutual Funds
30.51% Other Institutional Investors
36.14% Public Companies and
Individual Investors
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $1.64 and its highest was $12.51 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $554.33M.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is Aug 07, 2025 which is in 81 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on May 08, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.118.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.29.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 333,934,400 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went down -44.795%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
---
Iovance Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.54 (595.18% Upside)
$11.54 (595.18% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 77%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.08%
12-Months-Change
Fundamentals
Return on Equity
-51.85%
Trailing 12-Months
Asset Growth
11.14%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
---
IOVA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment. While there are significant achievements like strong first-year revenue, successful international compliance, and positive market expansion prospects, these are tempered by challenges such as a decline in first-quarter revenue, manufacturing issues, a cautious revenue outlook, and increased costs.Read More>---
IOVA Stock 12 Month Forecast
Average Price Target
$11.54
▲(595.18% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Ardelyx
―
Viridian Therapeutics
―
Syndax Pharmaceuticals
―
89bio
―
---